The feasibility and precision of clinical trials for the treatment of MS must be improved Subsequent to the approval by the Food and Drug Administration of the United States of interferon beta-1b as a safe and effective, though not curative, treatment for relapsing-remitting MS, the testing of other agents in this disease has been undertaken or is anticipated. This report summarises the discussions and recommendations of an international workshop held to review critically the elements of current MS therapeutic trials and to identify the most important aspects of clinical evaluation, study design and data analysis that would allow agents for MS to be tested as accurately, rapidly and economically as possible. While acknowledging the many uncertainties about the pathophysiology and natural history of MS, the workshop participants made recommendations about the preferred components to be used in the design of trials which may be different depending on the treatment goal and agent studied. It was concluded that the formulation of a useful clinical trial design must be based on specific guidelines for clinical scales and imaging for which task forces were recommended and subsequently appointed.
1 The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, placebo-controlled trial. Neurology43: 655–661.
2.
2 Brown JR, et al. (1979) The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology21: 1–23.
3.
3 Herndon RM, Murray TJ. (1983) Proceedings of the international conference on therapeutic trials in multiple sclerosis. Arch Neurol40: 663–710.
4.
4 Kurtzke JF. (1955) A new scale for evaluating disability in multiple sclerosis. Neurology5: 580–583.
5.
5 Kurtzke JF. (1961) On the evaluation of disability in multiple sclerosis. Neurology11: 686–694.
6.
6 Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology33: 1444–1452.
7.
7 Noseworthy JH, et al. (1990) Inter-rater variability with the expanded disability status scale (EDSS) and functional systems (FS) in multiple sclerosis clinical trials. Neurology40: 971–975.
8.
8 Sipe JC, et al. (1984) A neurological rating scale (NRS) for use in multiple sclerosis. Neurology34: 1368–1372.
9.
9 Cook SD, et al. (1986) Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet1: 1405–1409.
11 Redekop HK, Paty DW. (1991) Computerized scoring of neurologic impairment in multiple sclerosis. Ann Neurol30: 255.
12.
12 Spilker B. (1991) Guide to Clinical Trials.Raven Press: New York, pp 27–58.
13.
13 Food and Drug Administration. (1992) New Drug, Antibiotic and Biological Drug Product Regulations; Accelerated Approval; Final Rule. 21 CFR 314.510.Fed Reg57(239): 58941–58960.
14.
14 Merrill JE. (1992) Proinflammatory and anti-inflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J Immunother12: 167–170.
15.
15 Compston A. (1993) Inflammation and the brain. Mol Chem Neuropathol19: 47–64.
16.
16 Bednarik J, Kadanka Z. (1992) Multimodal sensory and motor evoked potentials in a 2-year follow-up study of MS patients with relapsing course. Acta Neurol Scand86: 15–18.
17.
17 Nuwer MR, et al. (1987) Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology37: 1754–1761.
18.
18 Isaac C, et al. (1988) Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology38: 1511–1515.
19.
19 Willoughby EW, et al. (1989) Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol25: 43–49.
20.
20 Kermode AC, et al. (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain113: 1477–1489.
21.
21 Harris JO, et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol29: 548–555.
22.
22 Katz D, et al. (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol34: 661–669.
23.
23 Miller DH, et al. (1988) Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain111: 927–939.
24.
24 McFarland HF, et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol32: 758–766.
25.
25 Barkhoff, et al. (1992) Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs. clinical findings in determining disease activity. Am J Roentgenol159: 1041–1047.
26.
26 Grossman RI, et al. (1988) Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology169: 117–122.
27.
27 Albert PS, et al. (1994) Time series for modeling counts from a relapsing-remitting disease: application to modeling disease activity in multiple sclerosis. Stat Med13: 453–466.
28.
28 Paty DW, Li DK. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 662–667.
29.
29 Smith ME, et al. (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neural33: 480–489.
30.
30 Filippi M, et al. (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology44: 635–641.
31.
31 Matthews PM, et al. (1991) Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology41: 1251–1256.
32.
32 Grossman RI, et al. (1992) MR proton spectroscopy in multiple sclerosis. Am J Neuroradiol13: 1535–1543.
33.
33 Minderhoud JM, et al. (1992) In vivio phosphorus magnetic resonance spectroscopy in multiple sclerosis. Arch Neural49: 161–165.
34.
34 Narayana PA, et al. (1992) Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imaging2: 263–270.
35.
35 Dousset V, et al. (1992) Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology182: 483–491 [published erratum in Radiology (1992) 183: 878].
36.
36 Miller DH, et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action guidelines. J Neural Neurosurg Psychiatr54: 683–688.
37.
37 Efron B, Tibshirani R. (1991) Statistical data analysis in the computer age. Science253: 390–395.
38.
38 Barkhoff, et al. (1992) A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology42: 63–67.
39.
39 Miller DH, et al. (1992) High dose steroids in the acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neural Neurosurg Psychiatr55: 450–453.
40.
40 Whitaker JN, Benveniste EN, Zhou SR. (1990) Cerebrospinal fluid. In: Handbook of Multiple Sclerosis, SD Cook (ed.) Marcel Dekker: New York, pp 251–270.
41.
41 Tourtellotte WW, et al. (1980) Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and cortico-steroids. Neurology30: 1155–1162.
42.
42 Whitaker JN, Snyder DS. (1982) Myelin components in the cerebrospinal fluid in diseases affecting central nervous system myelin. Clin Immunol Allergy2: 469–482.
43.
43 Cohen SR, Herndon RM, McKhann GM. (1976) Radio-immunoassay of myelin basic protein in spinal fluid: an index of active demyelination. N Engl J Med295: 1455–1457.
44.
44 Whitaker JN. (1977) Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis. Neurology27: 911–920.
45.
45 Warren KG, et al. (1986) Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neural Sci13: 25–30.
46.
46 Whitaker JN, et al. (1993) Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann Neural33: 10–17.
47.
47 Sharief MK, Hentges R. (1991) Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med325: 467–472.
48.
48 Adachi K, Kumamoto T, Araki S. (1990) Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neural28: 687–691.
49.
49 Noseworthy JH, et al. (1993) TNF-alpha in multiple sclerosis. Neurology43: A355.
50.
50 Fesenmeier JT, et al. (1991) Cerebrospinal fluid levels of myelin basic protein-like material and soluble inter leukin-2 receptor in multiple sclerosis. J Neuroimmunol34: 77–80.
51.
51 Martin R, McFarland HF, McFarlin DE. (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol10: 153–187.
53 Hartung H-P. Immune-mediated demyelination. (1993) Ann Neural33: 563–567.
54.
54 Whitaker JN. (1987) The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis. Ann Neural22: 648–655.
55.
55 Mehta PD, et al. (1991) Increased free light chains in the urine of patients with multiple sclerosis. Neurology41: 540–544.
56.
56 Whitaker JN, et al. (1994) Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis.Ann Neural, 35: 577–585.
57.
57 Multiple Sclerosis Study Group. (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blind, placebo-con trolled clinical trial.Ann Neural27: 591–605.
58.
58 Beck RW, et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med329: 1764–1769.
59.
59 Goodkin DE, Kanoti GA. (1994) Ethical considerations raised by approval of interferon beta-1b for the treatment of multiple sclerosis. Neurology44: 166–170.
60.
60 McDonald WI, Miller DH, Thompson AJ. (1994) Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of beta-interferon. Ann Neural36: 14–18.
